The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

According to Chang, these findings suggest that “OTX-TKI has more widespread effects on overall retinal leakage and ...

This case, Singh notes, has profoundly influenced his philosophy of glaucoma management: balancing surgical risk with the ...

Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...

Their discussion sheds light on the importance of physician advocacy in ophthalmology—from shaping policy and protecting patients to building community.

Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value ...

Researchers from New York Eye and Ear Infirmary of Mount Sinai, New York, reported that subretinal drusenoid deposits (SDDs) ...

Stephen Tsang, MD, PhD, professor at Columbia University and attending physician at NewYork-Presbyterian Hospital, shared encouraging early findings on the use of optogenetic therapy for patients with ...

Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for ...

The Eye Care Network sat down with Rajesh K. Rajpal, MD, ophthalmologist and founder of See Clearly Vision Group in McLean, ...

Dompé was selected by the US Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority ...

DAVIO-2 for wet AMD and VERONA for DME. In the DAVIO-2 trial, patients previously treated with approximately 10 injections in ...